Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN)

References

• D’Amico D, Grazzi L, Bussone G, et al. Are depressive symptomatology, self-efficacy, and perceived social support related to disability and quality of life in patients with chronic migraine associated to medication overuse? Data from a cross-sectional study. Headache. 2015;55(5):636–645.
   PubMed Web of Science ®Google Scholar
• Lanteri-Minet M. Economic burden and costs of chronic migraine. Curr Pain Headache Rep. 2014;18(1):385.
   PubMed Web of Science ®Google Scholar
• Mao X, Shrestha S, Baser O, et al. A retrospective analysis of the economic burden among patients diagnosed with chronic migraine using the Veterans Health Administration medical data. Value Health. 2015;18(3):A282–A283.
   Web of Science ®Google Scholar
• Aurora SK, Brin MF. Chronic migraine: an update on physiology, imaging, and mechanism of action of two available pharmacologic therapies. Headache. 2017;57(1):109–125.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.
   PubMed Web of Science ®Google Scholar
• Weatherall MW. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis. 2015;6(3):115–123.
   PubMed Web of Science ®Google Scholar
• Turner DP, Smitherman TA, Penzien DB, et al. Rethinking headache chronification. Headache. 2013;53(6):901–907.
   PubMed Web of Science ®Google Scholar
• Schwedt TJ. Chronic migraine. BMJ. 2014;348:g1416.
   PubMed Web of Science ®Google Scholar
• May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12(8):455–464.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55 Suppl 2(Suppl 2):103–122.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8):1157–1168.
   PubMed Web of Science ®Google Scholar
• Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10):1456–1470.
   PubMed Web of Science ®Google Scholar
• Raval AD, Shah A. National trends in direct health care expenditures among US adults with migraine: 2004 to 2013. J Pain. 2017;18(1):96–107.
   PubMed Web of Science ®Google Scholar
• Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19(5):703–711.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Schwedt TJ, Vo P, et al. Healthcare resource use and indirect costs associated with migraine in Italy: results from the My Migraine Voice survey. J Med Econ. 2021;24(1):717–726.
   PubMed Web of Science ®Google Scholar
• Negro A, Sciattella P, Rossi D, et al. Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. J Headache Pain. 2019;20(1):120.
   PubMed Web of Science ®Google Scholar
• Stovner LJ, Andrée C, Eurolight Steering Committee. Impact of headache in Europe: a review for the Eurolight project. J Headache Pain. 2008;9(3):139–146.
   PubMed Web of Science ®Google Scholar
• Goldberg LD. The cost of migraine and its treatment. Am J Manag Care. 2005;11(2 Suppl):S62–S67.
   PubMed Web of Science ®Google Scholar
• Tepper D. Medication overuse headache. Headache. 2017;57(5):845–846.
   PubMed Web of Science ®Google Scholar
• Shah AM, Bendtsen L, Zeeberg P, et al. Reduction of medication costs after detoxification for medication-overuse headache. Headache. 2013;53(4):665–672.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337–1345.
   PubMed Web of Science ®Google Scholar
• Diener HC, Solbach K, Holle D, et al. Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options. Clin Med. 2015;15(4):344–350.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the Second International Burden of Migraine Study (IBMS-II). Headache. 2013;53(4):644–655.
   PubMed Web of Science ®Google Scholar
• Estemalik E, Tepper S. Preventive treatment in migraine and the new US guidelines. Neuropsychiatr Dis Treat. 2013;9:709–720.
   PubMed Web of Science ®Google Scholar
• Ford JH, Schroeder K, Nyhuis AW, et al. Cycling through migraine preventive treatments: implications for all-cause total direct costs and disease-specific costs. JMCP. 2019;25(1):46–59.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–1088.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–1454.
   PubMed Web of Science ®Google Scholar
• Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–e2221.
   PubMed Web of Science ®Google Scholar
• Ford JH, Foster SA, Stauffer VL, et al. Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine. PPA. 2018;12:2413–2424.
   Web of Science ®Google Scholar
• Rothrock JF, Bloudek LM, Houle TT, et al. Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine. Headache. 2014;54(10):1565–1573.
   PubMed Web of Science ®Google Scholar
• Negro A, Curto M, Lionetto L, et al. A two years open-label prospective study of onabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015;17:1.
   PubMed Web of Science ®Google Scholar
• Vikelis M, Argyriou AA, Dermitzakis EV, et al. Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment. J Headache Pain. 2018;19(1):87.
   PubMed Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434.
   PubMed Web of Science ®Google Scholar
• Halker Singh RB, Aycardi E, Bigal ME, et al. Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: post-hoc analyses from phase 2 trials. Cephalalgia. 2019;39(1):52–60.
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Ashina M, Reuter U, et al. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials. J Headache Pain. 2021;22(1):81.
   PubMed Web of Science ®Google Scholar
• Tiseo C, Ornello R, Pistoia F, et al. How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice. J Headache Pain. 2019;20(1):49.
   PubMed Web of Science ®Google Scholar
• Friedman BW, West J, Vinson DR, et al. Current management of migraine in US emergency departments: an analysis of the National Hospital Ambulatory Medical Care Survey. Cephalalgia. 2015;35(4):301–309.
   PubMed Web of Science ®Google Scholar
• Friedman BW. Managing migraine. Ann Emerg Med. 2017;69(2):202–207.
   PubMed Web of Science ®Google Scholar
• Friedman BW, Serrano D, Reed M, et al. Use of the emergency department for severe headache. A population-based study. Headache. 2009;49(1):21–30.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301–315.
   PubMed Web of Science ®Google Scholar
• Bhandari A, Wagner T. Self-reported utilization of health care services: improving measurement and accuracy. Med Care Res Rev. 2006;63(2):217–235.
   PubMed Web of Science ®Google Scholar
• Ritter PL, Stewart AL, Kaymaz H, et al. Self-reports of health care utilization compared to provider records. J Clin Epidemiol. 2001;54(2):136–141.
   PubMed Web of Science ®Google Scholar
• D'Amico D, Grazzi L, Curone M, et al. Cost of medication overuse headache in Italian patients at the time-point of withdrawal: a retrospective study based on real data. Neurol Sci. 2017;38(Suppl 1):3–6.
   PubMed Web of Science ®Google Scholar
• Lantéri-Minet M, Duru G, Mudge M, et al. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31(7):837–850.
   PubMed Web of Science ®Google Scholar